The present invention refers to a new enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9, 11-dehydroderivatives starting from the corresponding 17α,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17α-propionate and 9,11-dehydro-cortexolone 17α-butanoate.

The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. This is delivered using a composition comprising P. acnes phage-derived endolysins where the actives are maintained at conditions like use of non-ionic polymers and specific pH and electrolytes range that ensure maximal inhibition efficacy.

The present invention relates to a method and a composition to prevent or treat acne by selective inhibition of P. acnes bacteria. This is delivered using a composition comprising P. acnes phage-derived endolysins where the actives are maintained at conditions like use of non-ionic polymers and specific pH and electrolytes range that ensure maximal inhibition efficacy.

It is disclosed an improved transdermal sunscreen composition including porphyrin, porphyrin analogues and/or porphyrin precursors (particularly 5-aminolevulinic acid, ALA) in a sub-therapeutic dose in combination with vitamin D3 or its analogues/derivatives in a transdermal carrier or carrier system to generate biomedical effects on reducing photodamaged skin conditions, inducing skin rejuvenation and compensating vitamin D3 for sunscreen-mediated vitamin D3 reduction/deficiency while simultaneously blocking harmful UV radiation from reaching and harming DNA in the cells of the skin.

A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively.

Disclosed is a topical composition comprising: (i) an antimicrobial active which is at least one of hydroxamic acids or hydroxamic acid derivatives; and (ii) an atractylenolide compound; wherein weight ratio of the amount of said atractylenolide compound to that of said antimicrobial active is at least 5:1. Also disclosed is a non-therapeutic method of providing topical antimicrobial benefit on a topical surface of a human or animal body comprising a step of applying a safe and effective amount of the topical antimicrobial composition.

The invention relates to methods of using an effective amount of activated protein C (APC) to treat an individual for a skin disorder characterised by the presence of hyperproliferative keratinocytes.

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis. ##STR00001##

The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis. ##STR00001##